SGR-5573

SGR-5573 is a small molecule drug candidate discovered and developed by Schrödinger. As of October 2025, there is no publicly available detailed information about its mechanism of action, specific target, primary indication, or clinical development status in peer-reviewed or clinical trial registries. SGR-5573 is referenced in the context of Schrödinger’s preclinical or discovery pipeline, but as of now, there are no substantive disclosures regarding disease focus, trial phases, or molecular targets. There are no records of SGR-5573 in major clinical trial registries or drug information databases, and no evidence that it has entered clinical development.